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Part 2 Sensitivity analyses Description of sensitivity analyses
The following sensitivity analyses were performed:
Outcome definition  Main outcome: morning cortisol <5nmol/l  Secondary outcome: morning cortisone <18nmol/l Sampling process Four Instructions to collect samples correctly: 1) Collect sample 15-30 minutes after waking 2) Collect samples on a "rest" day when wake without an alarm 3) Don't eat, drink, smoke or brush teeth until after sampling 4) Don't take any GCs until after sampling
Three categories for quality of sampling: 1 (no problems) meets 1)-4) 2 (minor problems) sample collection outside 1) but still <90 mins; or 'no' for ALL of 3) 3 (major problems) failed 1), 2), 3) OR 4), except as above; missing for any of 1)-4)
Analyses:
 All participants, regardless of any reported sampling problems  Only participants with no major sampling problems reported  Only participants with no sampling problems (major OR minor) reported Table S4 .2 Distribution of morning salivary cortisol and morning salivary cortisone by current GC use status n number; GC glucocorticoid; IQR interquartile range All participants (n=76) Former GC users (n=38) Current GC users (n=38) Cortisol, median (IQR) 6.5 (2.9-10.8) nmol/L 9.9 (6.6- Table S4 .4 Prevalence of low salivary cortisol/cortisone by current oral GC dose (current users only) sensitivity analyses GC glucocorticoid; CI confidence interval Results shown are number of participants with the outcome/ number of participants in group, prevalence of outcome in that group, and 95% confidence intervals.
Main outcome dose <5mg dose 5-10mg dose>=10mg All participants 3/10; prevalence 30% (95% CI -5%-65%) 14/19; prevalence 74% (95% CI 52%-95%) 8/9; prevalence 89% (95% CI 63%-115%) No major sampling problems 3/9; prevalence 33% (95% CI -5%-72%) 13/17; prevalence 76% (95% CI 54%-99%) 8/9; prevalence 89% (95% CI 63%-115%)
No major or minor sampling problems 3/9; prevalence 33% (95% CI -5%-72%) 10/13; prevalence 77% (95% CI 50%-103%) 5/5; prevalence 100% (95% CI 100%-100%) Secondary outcome dose <5mg dose 5-10mg dose>=10mg
All participants 2/10; prevalence 20% (95% CI -10%-50%) 14/19; prevalence 74% (95% CI 52%-95%) 9/9; prevalence 100% (95% CI 100%-100%) No major sampling problems 2/9; prevalence 22% (95% CI -12%-56%) 13/17; prevalence 76% (95% CI 54%-99%) 9/9; prevalence 100% (95% CI 100%-100%)
No major or minor sampling problems 2/9; prevalence 22% (95% CI -12%-56%) 11/13; prevalence 85% (95% CI 62%-107%) 5/5; prevalence 100% (95% CI 100%-100%) 
